about
Pharmacokinetic properties of azithromycin in pregnancyPharmacokinetics of chloroquine and monodesethylchloroquine in pregnancy.Transfer of parecoxib and its primary active metabolite valdecoxib via transitional breastmilk following intravenous parecoxib use after cesarean delivery: a comparison of naive pooled data analysis and nonlinear mixed-effects modeling.Development of a population pharmacokinetic model for parecoxib and its active metabolite valdecoxib after parenteral parecoxib administration in children.Desbutyl-lumefantrine is a metabolite of lumefantrine with potent in vitro antimalarial activity that may influence artemether-lumefantrine treatment outcome.Pharmacokinetic properties of conventional and double-dose sulfadoxine-pyrimethamine given as intermittent preventive treatment in infancy.Continuous infusions of meropenem in ambulatory care: clinical efficacy, safety and stability.Population pharmacokinetics of artemether, lumefantrine, and their respective metabolites in Papua New Guinean children with uncomplicated malaria.Meningeal inflammation increases artemether concentrations in cerebrospinal fluid in Papua New Guinean children treated with intramuscular artemether.Pharmacokinetics of a novel sublingual spray formulation of the antimalarial drug artemether in African children with malaria.Pharmacokinetics of a novel sublingual spray formulation of the antimalarial drug artemether in healthy adults.Pharmacokinetics of piperaquine transfer into the breast milk of Melanesian mothers.Population pharmacokinetics, tolerability, and safety of dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine-piperaquine in pregnant and nonpregnant Papua New Guinean women.Artemisinin-naphthoquine combination therapy for uncomplicated pediatric malaria: a pharmacokinetic study.Artemisinin-naphthoquine combination therapy for uncomplicated pediatric malaria: a tolerability, safety, and preliminary efficacy study.Pharmacokinetic comparison of two piperaquine-containing artemisinin combination therapies in Papua New Guinean children with uncomplicated malaria.Validation and Application of a Dried Blood Spot Ceftriaxone Assay.Safety, tolerability and pharmacokinetic properties of coadministered azithromycin and piperaquine in pregnant Papua New Guinean womenValidation and Application of a Dried Blood Spot Assay for Biofilm-Active Antibiotics Commonly Used for Treatment of Prosthetic Implant Infections.Pharmacokinetic properties of sulfadoxine-pyrimethamine in pregnant women.Pharmacokinetic properties of single-dose primaquine in Papua New Guinean children: feasibility of abbreviated high-dose regimens for radical cure of vivax malaria.Optimal antimalarial dose regimens for chloroquine in pregnancy based on population pharmacokinetic modelling.Use of quantitative pharmacology tools to improve malaria treatments.Optimal Antimalarial Dose Regimens for Sulfadoxine-Pyrimethamine with or without Azithromycin in Pregnancy Based on Population Pharmacokinetic Modeling.Penicillin Dried Blood Spot Assay for Use in Patients Receiving Intramuscular Benzathine Penicillin G and Other Penicillin Preparations To Prevent Rheumatic Fever.Naphthoquine: An Emerging Candidate for Artemisinin Combination Therapy.Treatment regimens for pregnant women with falciparum malaria.Pharmacokinetics and analgesic effectiveness of intravenous parecoxib for tonsillectomy ± adenoidectomy.Bradycardia and Hypothermia Complicating Azithromycin Treatment.Modeling C-reactive protein kinetic profiles for use as a clinical prediction tool in patients with Staphylococcus aureus bacteremia.A trial of combination antimalarial therapies in children from Papua New Guinea.Pharmacokinetic considerations for use of artemisinin-based combination therapies against falciparum malaria in different ethnic populations.Regarding "Lactation Status and Studies of Pyrimethamine Pharmacokinetics in Pregnancy".Taste evaluation of a novel midazolam tablet for pediatric patients: In vitro drug dissolution, in vivo animal taste aversion and clinical taste perception profiles.Simultaneous determination of pentoxifylline, metabolites M1 (lisofylline), M4 and M5, and caffeine in plasma and dried blood spots for pharmacokinetic studies in preterm infants and neonates.Generation bias in meta-analysis of duration of dual antiplatelet therapy following drug-eluting stent.Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis.Effects of maturation and size on population pharmacokinetics of pentoxifylline and its metabolites in very preterm infants with suspected late-onset sepsis or necrotizing enterocolitis: a pilot study incorporating clinical outcomesValidation of a Dried Blood Spot Ceftriaxone Assay in Papua New Guinean Children with Severe Bacterial InfectionsA novel, palatable paediatric oral formulation of midazolam: pharmacokinetics, tolerability, efficacy and safety
P50
Q33558917-67616240-5D20-4432-9CDB-6C3E02F4B84EQ33676120-B8BA0D14-CEB4-4C97-826F-5B01C8C82C4AQ34161575-D13091AF-EE5C-4261-8DA9-2D84308DEDF7Q34636955-6893159F-B6C3-4FBD-93F9-8353304A6578Q34737444-4A5FCF85-5228-4C1A-9923-F15D47F34754Q34737758-2162444A-BA2D-447F-863A-732DA25F07BDQ35206338-3BAD55F0-B94D-48AA-8954-5CB0F180C9FAQ35363704-5F0EC416-FFB7-4ADE-967E-14DC5E448DE5Q35363936-2A60009B-C5F7-4960-8D1F-6AECB23DCFE1Q35607695-6AECAF24-78FB-4692-B71B-273972EC3AFAQ35607781-EA5F3A1F-1E0A-49A1-B1C0-AA730BC7BC12Q35746024-A21F2F87-FE14-426E-A803-F6252EEE6FE2Q35746240-689FCCCA-E523-4F74-B47F-9242E5200523Q35941440-AD15B8F8-A6A4-401F-B921-F53172A97FC5Q35941455-06DA4936-2AF2-4E25-807A-1CABA44FEA71Q36018642-35D3E90F-ABB4-4E09-88EA-7010F88EC477Q36439065-E78693C3-55EF-4EB6-A143-2E03EBEE6AEBQ37030663-69373849-1E30-4931-8172-B2480F2F5CBCQ37120112-9A785CF9-BDEF-464C-AC26-DA241F9CD259Q37392749-8250BCF6-CB89-4B1A-91E1-86615E2AE3C0Q37544499-C27C647D-CDAE-471D-9A93-D16543DDA9ACQ38663801-C5DE5531-395D-4041-BBBA-3AB95EE27C58Q38664529-018FB4BD-0BEF-4380-88DC-02A4C456C369Q38752586-5365ACFA-8D05-4CB8-938C-40E2D5AC08A7Q38755675-FEBE8AEB-BA51-4CC0-90E3-95030CCA409AQ38807529-2D5FAA1F-3903-4325-81EB-6F10B94B5E15Q38870452-2403876B-605A-42DE-89CF-5FDE8B780665Q39251488-A9E65ECD-FD66-4018-AB4B-B83F7A5B82DDQ40097878-39FC6CB2-D03B-4CFF-AD9A-75E3B59274A8Q40965048-6ED53964-77B5-45BF-96B7-86120C823213Q41939607-072ED660-80D8-4CC9-9E9D-01CF0CE0CCE7Q46405195-287321D0-9D7C-45BE-9007-BA316E2D4554Q47148174-C2783EEF-28CF-41F7-8764-90ED5887846DQ47234952-C5431C81-94CB-450E-BD82-7D489E0B0D8EQ47888160-1FDA2910-3FF5-47F8-8B84-191BDD0C187DQ53153108-8D83DAEA-7633-428B-A635-9BF0CA1E475EQ55449589-C1D671BA-1ABD-4994-9767-262B5986060EQ59573977-33E26748-7953-4EB1-B7DC-42F482AD0D70Q59573978-C4AAAF70-645C-442E-8A1E-430A1B8074BFQ59573980-EF6BBE6E-F40D-47D4-9EE9-68C329843C09
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Sam Salman
@ast
Sam Salman
@en
Sam Salman
@es
Sam Salman
@nl
Sam Salman
@sl
type
label
Sam Salman
@ast
Sam Salman
@en
Sam Salman
@es
Sam Salman
@nl
Sam Salman
@sl
prefLabel
Sam Salman
@ast
Sam Salman
@en
Sam Salman
@es
Sam Salman
@nl
Sam Salman
@sl
P106
P1153
25926080000
P21
P31
P496
0000-0002-8276-6784